Company

Biothera Pharmaceuticals Appoints Andrew D.C. LaFrence Chief Financial Officer

EAGAN, MN — May 16, 2018 — Biothera Pharmaceuticals, Inc., announced the appointment of Andrew D.C. LaFrence, CPA as Senior Vice President and Chief Financial Officer, effective May 29.  Biothera Pharmaceuticals is a clinical stage immuno-oncology company developing a novel immunotherapy in combination with immune checkpoint inhibitors for multiple types of cancer. Mr. LaFrence has 34 years of accounting and finance experience, including executive management...

Read More


Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)

Study Is Second Clinical Research Collaboration with Merck EAGAN, MN — February 6, 2018 — Biothera Pharmaceuticals, Inc. announced today that patient treatment has commenced in its Phase 2 clinical study in squamous cell carcinoma of the head and neck (SCCHN).  The research collaboration with Merck (known as MSD outside the United States and Canada) will evaluate Biothera’s Imprime PGG in combination with KEYTRUDA® (pembrolizumab),...

Read More


Biothera Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference

EAGAN, MN — November 21, 2017 — Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the 29th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 11:10 a.m. Eastern Time in New York, NY.  Mr. Labinger will provide an overview of Biothera Pharmaceuticals and an update on its clinical development plans in oncology. About Biothera Pharmaceuticals, Inc....

Read More


Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck’s Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer

EAGAN, MN — December 10, 2015 — Biothera Pharmaceutical Inc., today announced plans for a Phase 1b/2 clinical study in non-small lung cancer (NSCLC) patients to evaluate the ability of Biothera’s Imprime PGG to enhance responses to pembrolizumab (Keytruda®), the anti-PD-1 antibody from Merck (NYSE:MRK), known as MSD outside the United States and Canada. Merck will provide funding and clinical supplies of pembrolizumab for the...

Read More


Biothera Pharmaceutical Inc. Appoints Barry Labinger as Chief Executive Officer

EAGAN, MN — December 9, 2015 — Biothera Pharmaceutical Inc. announced today the appointment of Barry Labinger as Chief Executive Officer, effective December 14. Biothera Pharmaceutical is developing a novel cancer immunotherapy that triggers a robust, coordinated immune response against a wide range of cancers. Mr. Labinger has nearly three decades of pharmaceutical and biotech industry experience, with leading roles at Emergent BioSolutions, Human Genome...

Read More


Biothera’s Imprime PGG and Monoclonal Antibody Therapy Alleviates Immune Suppression in Tumor Microenvironment and Increases Cancer Cell Killing

Company to Present New Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting NATIONAL HARBOR, MD — November 6, 2015 — New research provides additional scientific evidence that Biothera’s mid clinical stage cancer immunotherapy Imprime PGG acts as an immune ignition switch that enables the body to recognize and kill tumor cells. The company will present the data today at the Society for Immunotherapy...

Read More


Biothera’s Imprime PGG and Anti-Angiogenic Antibodies Work in Concert to Re-orient the Immune Microenvironment to Support Cancer Killing, Study Finds

BOSTON, November 6, 2015 — New preclinical research demonstrating the combination of Biothera’s Imprime PGG and anti-angiogenic antibodies re-orients the immune microenvironment to suppress tumor growth will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Imprime PGG is an immune potentiator that represents the next step in immune oncology. This mid clinical stage cancer immunotherapeutic is a first-in-class, well-tolerated,...

Read More


Biothera to Present Three Abstracts at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EAGAN, MN — November 2, 2015 — Biothera, a clinical stage biotechnology company pioneering the development of immune potentiators known as PAMPs for cancer immunotherapy, will present three abstracts at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5–9 at the Hynes Convention Center in Boston. PAMPs (Pathogen Associated Molecular Patterns) serve as critical recognition signals...

Read More


Kerry Acquires Wellmune® from Biothera Inc.

Tralee, Ireland and Eagan, Minnesota, U.S.A. ─ October 21, 2015 ─ Kerry Group plc, the global taste and nutrition company, has acquired Wellmune® from Biothera Inc., a natural food, beverage and supplement ingredient that is clinically proven to help strengthen the immune system. “At Kerry, cutting-edge science and technology informs everything we help shape and create. The addition of Wellmune to our portfolio offers Kerry...

Read More